Clinical Trial Update: A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in China evaluating sintilimab plus chemotherapy versus chemotherapy alone as adjuvant therapy for gastric or gastroesophageal junction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING